KMS-12-PE Cells

Categories: Myeloma cell lines Description: The KMS-12-PE cell line, established from the pleural effusion of the same patient, differs significantly from KMS-12-BM in several aspects. KMS-12-PE cells represent a more terminally differentiated plasma cell stage, as indicated by the absence of CD20 but continued expression of CD38 and PCA-1. A striking feature of KMS-12-PE is its ability to ectopically produce and secrete a salivary type of amylase, both in the patient's pleural effusion and in culture, making it unique among human myeloma cell lines. This phenomenon is associated with a chromosomal deletion near the region where the amylase gene is located, specifically del(1)(p22->pter), observed in a significant proportion of KMS-12-PE cells. Despite these distinct differences, both KMS-12-PE and KMS-12-BM share the same clonal marker, the translocation t(11,14)(q13,q32), which is common in myeloma cases. However, KMS-12-PE cells show fewer chromosomal abnormalities than KMS-12-BM and tend to be hypodiploid. Like KMS-12-BM, KMS-12-PE does not produce immunoglobulins, either in surface or secretory form, even though the cells have well-developed endoplasmic reticulum. The lack of tumorigenicity in both cell lines, despite their aggressive in vitro growth, and their stable long-term proliferation in serum-free medium make them valuable tools for studying myeloma biology, particularly in the context of non-Ig-producing myeloma. Organism: Human Tissue: Pleural effusion Disease: Multiple Myeloma Synonyms: KMS 12 PE, KMS-12_PE, KMS-12PE, KMS12-PE, KMS12PE, Kawasaki Medical School-12-Pleural Effusion Age: 64 years Gender: Female Ethnicity: Japanese Morphology: Round cells Cell Type: B cell Growth Properties: Suspension, single cells and small clusters Citation: KMS-12-PE (Cytion catalog number 300286) Biosafety Level: 1 Ncbi_ Taxid: 9606.0 Cellosaurus Accession: CVCL_1333 Surface Antigens: CD3 -, CD4 -, CD13 -, CD14 -, CD15 -, CD19 -, CD20 -, CD34 -, CD38 +, CD138 +, HLA-DR +, PCA-1 + Tumorigenic: Not tumorigenic in nude mice Products: No immunoglobulin production Mutational Profile: Translocation: t(11,14)(q13,q32) Culture Medium: RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) Supplements: Supplement the medium with 10% FBS Subculturing: Maintain cultures by periodically adding or replacing the medium. Initiate cultures with a density of 5 x 105 cells/ml and keep the cell concentration within the range of 3 x 105 to 1 x 106 cells/ml for optimal growth. Seeding Density: 5 x 105 cells/ml Freeze Medium: As a cryopreservation medium, use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Thawing And Culturing Cells: Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently. Centrifuge the mixture at 300 x g for 3 minutes to separate the cells and carefully discard the supernatant containing residual freezing medium. Gently resuspend the cell pellet in 10 ml of fresh culture medium. For adherent cells, divide the suspension between two T25 culture flasks, for suspension cultures, transfer all the medium into one T25 flask to promote effective cell interaction and growth. Adhere to established subculture protocols for continued growth and maintenance of the cell line, ensuring reliable experimental outcomes. Sterility: Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. Safety Precautions: When planning to store a cryovial in liquid nitrogen for future thawing, it is mandatory to adhere to stringent safety measures. Appropriate protective gloves and clothing are essential, and the use of a face mask or safety goggles is required during the transfer of frozen samples to or from the liquid nitrogen tank. This is to mitigate the risk of injury from potential cryovial explosions upon removal, which can result in the projection of sharp fragments. Warranty: We stand by the promise of delivering products with high cell viability and robust culture performance. To achieve the best results, please make sure you follow the storage and culture instructions detailed in the product information sheet closely. Your adherence to these guidelines is key to success. Subject To Material Transfer Agreements: If you intend to use Cytion cell lines solely for internal research at a single research site, please complete and sign our Material Transfer Agreement (MTA) and submit it along with your order.For any commercial applications - including but not limited to fee-for-service work, quality control testing, product release, diagnostic use, or regulatory studies - please complete the Intended Use Form so we can prepare a suitable agreement tailored to your project.Please note: The MTA applies only to certain cell lines. If this notice and the MTA document appear on a product page, the agreement is applicable. For cell lines not covered by the MTA, no reference to the agreement will be shown. The MTA is not valid for customers in the Americas, China, or Taiwan. Please contact our U.S. entity to receive the appropriate agreement. Required Product 1: 820700a Required Product 3: 860015.0 Required Product 4: 830100.0